NASDAQ:VINC

Vincerx Pharma (VINC) Stock Forecast, Price & News

$1.01

-0.03 (-2.88%)

(As of 09/29/2023 ET)

Compare

Today's Range: $0.98
▼
$1.09
50-Day Range: $0.66
▼
$1.20
52-Week Range: $0.63
▼
$1.95

Volume: 176,966 shs
Average Volume: 93,193 shs
Market Capitalization: $21.59 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Vincerx Pharma MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 296.0% Upside
$4.00 Price Target
Short Interest: Healthy
1.31% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$26,030 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.85) to ($0.44) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.89 out of 5 stars

Medical Sector

52nd out of 973 stocks

Pharmaceutical Preparations Industry

12th out of 449 stocks

3.5

Analyst's Opinion

Consensus Rating
Vincerx Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, Vincerx Pharma has a forecasted upside of 296.0% from its current price of $1.01.
Amount of Analyst Coverage
Vincerx Pharma has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.31% of the float of Vincerx Pharma has been sold short.
Short Interest Ratio / Days to Cover
Vincerx Pharma has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Vincerx Pharma has recently decreased by 11.81%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Vincerx Pharma does not currently pay a dividend.
Dividend Growth
Vincerx Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VINC.

3.8

News and Social Media Coverage

News Sentiment
Vincerx Pharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Vincerx Pharma this week, compared to 0 articles on an average week.
MarketBeat Follows
2 people have added Vincerx Pharma to their MarketBeat watchlist in the last 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vincerx Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $26,030.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
20.60% of the stock of Vincerx Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
56.46% of the stock of Vincerx Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Vincerx Pharma are expected to grow in the coming year, from ($1.85) to ($0.44) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vincerx Pharma is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vincerx Pharma is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vincerx Pharma has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Vincerx Pharma (NASDAQ:VINC) Stock

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

VINC Price History

30 days | 90 days | 365 days | Advanced Chart

VINC Stock News Headlines

September 19, 2023 | finance.yahoo.com

Vincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023

September 14, 2023 | finance.yahoo.com

Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943

September 30, 2023 | Altimetry (Ad)

Advisor to FBI: Sell META now

Stocks just keep going up. But all isn’t what it seems, according to an FBI and Pentagon advisor. Find out what he knows, here.

September 8, 2023 | benzinga.com

DelveInsight Evaluates a Robust B-Cell Lymphoma Clinical Trial as 160+ Influential Pharma Companies to Set Foot in the 7MM

August 23, 2023 | msn.com

FDA approves Vincerx’s IND application for trial of VIP943

August 23, 2023 | benzinga.com

Cancer Antibody Drug Conjugates Market Size Clinical Trials Insight

August 23, 2023 | proactiveinvestors.com

Vincerx Pharma receives FDA clearance for early-stage leukemia trial

August 22, 2023 | marketwatch.com

Vincerx Pharma Shares Jump 8% Premarket After FDA Clearance for Clinical Trial

September 30, 2023 | Altimetry (Ad)

Advisor to FBI: Sell META now

Stocks just keep going up. But all isn’t what it seems, according to an FBI and Pentagon advisor. Find out what he knows, here.

August 10, 2023 | finance.yahoo.com

Vincerx Pharma (NASDAQ:VINC) Will Have To Spend Its Cash Wisely

August 7, 2023 | finance.yahoo.com

Vincerx Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update

May 23, 2023 | finance.yahoo.com

Richter's Syndrome Pipeline Insight Report 2023: Featuring Secura Bio, Genmab, Genentech, Acerta Pharma & Vincerx Pharma

May 15, 2023 | markets.businessinsider.com

Vincerx Pharma Inc (VINC) Gets a Buy from SVB Securities

May 12, 2023 | finanznachrichten.de

Vincerx Pharma, Inc.: Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 11, 2023 | finance.yahoo.com

Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

April 19, 2023 | msn.com

Vincerx Pharma's Preclinical Data From Blood Cancer Candidate Shows Efficacy, Lower Toxicity

April 19, 2023 | finance.yahoo.com

Vincerx Pharma Presents Preclinical Data on VIP924, a First-in-Class Antibody-Drug Conjugate (ADC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

April 17, 2023 | finance.yahoo.com

Vincerx Pharma Presents Preclinical Data on Novel Small Molecule Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting 2023

April 17, 2023 | finance.yahoo.com

Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

March 30, 2023 | seekingalpha.com

VINC Vincerx Pharma, Inc.

March 28, 2023 | finance.yahoo.com

Vincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

February 6, 2023 | finance.yahoo.com

Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference

December 15, 2022 | msn.com

Peering Into Vincerx Pharma's Recent Short Interest

December 13, 2022 | finance.yahoo.com

Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236

December 11, 2022 | finance.yahoo.com

Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

November 10, 2022 | finance.yahoo.com

Vincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

November 3, 2022 | finance.yahoo.com

Vincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022

See More Headlines

Receive VINC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter.

VINC Company Calendar

Last Earnings: 8/07/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VINC
CUSIP: N/A
CIK: 1796129
Web: vincerapharma.com
Phone: 650-800-6676
Fax: N/A
Employees: 41
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.00
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +296.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.65)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-65,370,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -134.99%
Return on Assets: -104.51%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.47
Quick Ratio: 3.47

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.25 per share
Price / Book: 0.45

Miscellaneous

Outstanding Shares: 21,380,000
Free Float: 16,977,000
Market Cap: $21.59 million
Optionable: Not Optionable
Beta: 0.41

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Ahmed M. Hamdy M.D. (Age 58)
Founder, Chairman & CEO
Comp: $609.84k

Dr. Raquel E. Izumi Ph.D. (Age 53)
Founder, Pres, COO, Sec. & Director
Comp: $551.66k

Mr. Alexander A. Seelenberger M.B.A. (Age 44)
MBA, Chief Financial Officer
Comp: $458.03k

Mr. Tom C. Thomas J.D. (Age 64)
Founder, Gen. Counsel & Chief Legal Officer

Dr. John C. Byrd M.D.
Founder & Chairman of Scientific Advisory Board

Dr. Hans-Georg Lerchen Ph.D.
Chief Scientific Officer

Ms. Gabriela Jairala
Sr Exec. Director of Investor Relations & Corp. Communications

Ms. Karen Quarford
VP of Quality Operations & Compliance

Ms. Melissa Merrick SPHR
Sr. Director of People & Culture and Head of Human Resource

Dr. Beatrix Stelte-Ludwig Ph.D.
Exec. Chief Devel. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VINC Stock - Frequently Asked Questions

Should I buy or sell Vincerx Pharma stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vincerx Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VINC shares.
View VINC analyst ratings or view top-rated stocks.
What is Vincerx Pharma's stock price forecast for 2023?: 2 Wall Street analysts have issued 12-month price objectives for Vincerx Pharma's stock. Their VINC share price forecasts range from $3.00 to $5.00. On average, they anticipate the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 296.0% from the stock's current price.
View analysts price targets for VINC or view top-rated stocks among Wall Street analysts.
How have VINC shares performed in 2023?: Vincerx Pharma's stock was trading at $1.02 at the start of the year. Since then, VINC stock has decreased by 1.0% and is now trading at $1.01.
View the best growth stocks for 2023 here.
When is Vincerx Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our VINC earnings forecast.

How were Vincerx Pharma's earnings last quarter?: Vincerx Pharma, Inc. (NASDAQ:VINC) released its quarterly earnings results on Monday, August, 7th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.13.
What is Vincerx Pharma's stock symbol?: Vincerx Pharma trades on the NASDAQ under the ticker symbol "VINC."
How do I buy shares of Vincerx Pharma?: Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Vincerx Pharma's stock price today?: One share of VINC stock can currently be purchased for approximately $1.01.
How much money does Vincerx Pharma make?: Vincerx Pharma (NASDAQ:VINC) has a market capitalization of $21.59 million. The company earns $-65,370,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis.
How can I contact Vincerx Pharma?: Vincerx Pharma's mailing address is 260 SHERIDAN AVENUE SUITE 400, PALO ALTO CA, 94306. The official website for the company is vincerapharma.com. The company can be reached via phone at 650-800-6676.

This page (NASDAQ:VINC) was last updated on 9/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial